Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Lower ApoA1 ApoA1 ≤ 1.36 g/L, Higher ApoA1 ApoA1 > 1.36 g/L; ApoA1 apolipoprotein A1; BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; TG triglycerides; TC total cholesterol; LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; ApoB apolipoprotein B; BUN blood urea nitrogen; CR creatinine; FPG fasting plasma glucose; HbA1c hemoglobin A1c; CRP C-reactive protein; ALP alkaline phosphatase; 25(OH) D 25-hydroxyvitamin DBaseline characteristics of participants stratified by the osteoporosisNon-osteoporosis(n = 7555)Osteoporosis(n = 188)P valueAge, years48.76 ± 19.5866.63 ± 15.18< 0.001Sex, male, n (%)3887 (51.40%)23 (12.20%)< 0.001Race, n (%)< 0.001 Non-Hispanic White3372 (44.60%)142 (75.50%) Non-Hispanic Black1868 (24.70%)18 (9.60%) Mexican-American2074 (27.50%)26 (13.80%) Others241 (3.20%)2 (1.10%)Smoking status, n (%)0.199 Every day3493 (46.20%)99 (52.70%) Some days1998 (26.40%)46 (24.50%) Not at all2063 (27.30%)43 (22.90%)Comorbidities, n (%) Hypertension2762 (36.90%)110 (58.50%)< 0.001 Diabetes1156 (15.30%)47 (25.00%)< 0.001 Hypercholesterolemia1189 (33.10%)51 (38.30%)0.210 Gout234 (3.10%)11 (5.90%)0.033Medication, n (%) Hypotensive drugs1169 (16.70%)60 (33.90%)< 0.001 Hypoglycemic drugs424 (5.70%)19 (10.10%)0.010 Cholesterol-lowering drugs214 (8.00%)13 (13.50%)0.051BMI, kg/m226.77 ± 5.5426.69 ± 6.080.846SBP, mmHg125.89 ± 19.50135.84 ± 18.65< 0.001DBP, mmHg74.08 ± 10.6473.75 ± 9.540.679TG, mmol/L1.28 (0.88, 1.92)1.52 (1.05, 2.07)0.001TC, mmol/L5.36 ± 1.165.78 ± 1.09< 0.001LDL-C, mmol/L3.35 ± 1.003.60 ± 0.970.035HDL-C, mmol/L1.33 ± 0.401.49 ± 0.44< 0.001ApoA1, g/L1.44 ± 0.261.58 ± 0.29< 0.001ApoB, g/L1.07 ± 0.271.14 ± 0.29< 0.001BUN, mmol/L5.31 ± 2.265.97 ± 2.31< 0.001CR, umol/L96.56 ± 34.2293.50 ± 24.070.231Albumin, g/L42.38 ± 3.8940.67 ± 3.13< 0.001Uric acid, umol/L318.93 ± 90.08295.73 ± 94.030.001FPG, mmol/L5.24 (4.89, 5.68)5.38 (4.99, 5.89)0.010HbA1c, %5.51 ± 1.095.74 ± 1.320.005CRP, mg/dL0.21 (0.21, 0.44)0.21 (0.21, 0.44)0.063ALP, U/L84.46 ± 34.5892.58 ± 39.290.002Total calcium, mmol/L2.34 ± 0.112.36 ± 0.110.00325(OH) D, nmol/L55.52 ± 20.1354.58 ± 21.050.545Data were expressed as mean ± SD, median (interquartile range), or n (%)BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; TG triglycerides; TC total cholesterol; LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; ApoA1 apolipoprotein A1; ApoB apolipoprotein B; BUN blood urea nitrogen; CR creatinine; FPG fasting plasma glucose; HbA1c hemoglobin A1c; CRP C-reactive protein; ALP alkaline phosphatase; 25(OH) D 25-hydroxyvitamin D
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Association of apolipoprotein A1 with osteoporosis: a cross-sectional study
Source: Article title.
In this cross-sectional study, all participants were from the Third National Health and Nutrition.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association of apolipoprotein A1 with osteoporosis: a cross-sectional study
Cross-sectional study · BMC Musculoskeletal Disorders · 2023
Original publication title
Association of apolipoprotein A1 with osteoporosis: a cross-sectional study
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Although the current evidence shows that lipid metabolism and osteoporosis are closely related to cardiovascular disease, the association between ApoA1 and osteoporosis is still unknown. Therefore, the purpose of this study was to explore the relationship between ApoA1 and osteoporosis.
Source: BackgroundAbstract: What methods does the paper describe?
In this cross-sectional study, we included 7743 participants in the Third National Health and Nutrition Examination Survey. ApoA1 was regarded as an exposure variable and osteoporosis was considered as an outcome variable. Multivariate logistic regression analysis, sensitivity analysis, and receiver operator characteristic (ROC) were used to assess the association of ApoA1 with osteoporosis.
Source: MethodsAbstract: Summary
Higher levels of apolipoprotein A1 (ApoA1) were associated with higher risk of osteoporosis, which supports the argument that lipid metabolism is involved in bone metabolism.
Source: SummaryAbstract: Results
Participants with higher ApoA1 had higher rates of osteoporosis compared to participants with lower ApoA1 (P < 0.05). Individuals with osteoporosis had higher levels of ApoA1 than individuals without osteoporosis (P < 0.05). In multivariate logistic regression analysis adjusted for age, sex, race, hypertension, diabetes, gout, hypotensive drugs, hypoglycemic drugs, systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein B, blood urea nitrogen, albumin, uric acid, hemoglobin A1c, alkaline phosphatase and total calcium, higher ApoA1 was strongly associated with higher risk of osteoporosis, whether as a continuous variable or a categorical variable [Model 3, OR (95% CI), P value: 2.289 (1.350, 3.881), 0.002 and 1.712 (1.183, 2.478), 0.004].
And after excluding individuals with gout, the correlation between them remained and was significant (P < 0.01). And ROC analysis also showed that ApoA1 could predict the development of osteoporosis (AUC = 0.650, P < 0.001).
Source: ResultsAbstract: Conclusion
ApoA1 was closely associated with osteoporosis.
Source: ConclusionAuthors’ abstract
Summary
Higher levels of apolipoprotein A1 (ApoA1) were associated with higher risk of osteoporosis, which supports the argument that lipid metabolism is involved in bone metabolism.
Background
Although the current evidence shows that lipid metabolism and osteoporosis are closely related to cardiovascular disease, the association between ApoA1 and osteoporosis is still unknown. Therefore, the purpose of this study was to explore the relationship between ApoA1 and osteoporosis.
Methods
In this cross-sectional study, we included 7743 participants in the Third National Health and Nutrition Examination Survey. ApoA1 was regarded as an exposure variable and osteoporosis was considered as an outcome variable. Multivariate logistic regression analysis, sensitivity analysis, and receiver operator characteristic (ROC) were used to assess the association of ApoA1 with osteoporosis.
Results
Participants with higher ApoA1 had higher rates of osteoporosis compared to participants with lower ApoA1 (P < 0.05). Individuals with osteoporosis had higher levels of ApoA1 than individuals without osteoporosis (P < 0.05). In multivariate logistic regression analysis adjusted for age, sex, race, hypertension, diabetes, gout, hypotensive drugs, hypoglycemic drugs, systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein B, blood urea nitrogen, albumin, uric acid, hemoglobin A1c, alkaline phosphatase and total calcium, higher ApoA1 was strongly associated with higher risk of osteoporosis, whether as a continuous variable or a categorical variable [Model 3, OR (95% CI), P value: 2.289 (1.350, 3.881), 0.002 and 1.712 (1.183, 2.478), 0.004].
And after excluding individuals with gout, the correlation between them remained and was significant (P < 0.01). And ROC analysis also showed that ApoA1 could predict the development of osteoporosis (AUC = 0.650, P < 0.001).
Conclusion
ApoA1 was closely associated with osteoporosis.
Publication and source details
Original title: Association of apolipoprotein A1 with osteoporosis: a cross-sectional study
Xiaozhi Sun; Xiaotao Wu
BMC Musculoskeletal Disorders · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T20:16:14.337169+00:00
DOI: 10.1186/s12891-023-06264-6 · PMC9979473